Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on May 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on April 17th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Beiersdorf Aktiengesellschaft OTCMKTS: BDRFF on 5/2/2025.
• Purchased $1,001 - $15,000 in shares of Alkami Technology NASDAQ: ALKT on 4/30/2025.
• Purchased $1,001 - $15,000 in shares of Merck & Co., Inc. NYSE: MRK on 4/29/2025.
• Sold $1,001 - $15,000 in shares of DXC Technology NYSE: DXC on 4/29/2025.
• Sold $1,001 - $15,000 in shares of DOW NYSE: DOW on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Zions Bancorporation, National Association NASDAQ: ZION on 4/29/2025.
• Purchased $1,001 - $15,000 in shares of O'Reilly Automotive NASDAQ: ORLY on 4/29/2025.
• Purchased $1,001 - $15,000 in shares of McKesson NYSE: MCK on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Humana NYSE: HUM on 4/29/2025.

Crinetics Pharmaceuticals Price Performance

Shares of CRNX stock traded down $1.87 during trading hours on Tuesday, hitting $31.45. The stock had a trading volume of 418,624 shares, compared to its average volume of 1,025,082. The firm has a market capitalization of $2.94 billion, a PE ratio of -8.43 and a beta of 0.31. The stock's 50 day moving average is $31.94 and its 200 day moving average is $42.16. Crinetics Pharmaceuticals, Inc. has a twelve month low of $24.10 and a twelve month high of $62.53.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.05). The firm had revenue of $0.36 million for the quarter, compared to analyst estimates of $0.10 million. The business's revenue for the quarter was down 43.6% on a year-over-year basis. During the same period last year, the business earned ($0.93) EPS. As a group, equities analysts predict that Crinetics Pharmaceuticals, Inc. will post -3.73 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently weighed in on CRNX. Jefferies Financial Group raised Crinetics Pharmaceuticals from a "hold" rating to a "buy" rating and set a $55.00 price target for the company in a report on Wednesday, January 22nd. HC Wainwright reaffirmed a "buy" rating and set a $81.00 price target on shares of Crinetics Pharmaceuticals in a report on Monday, January 13th. Wolfe Research began coverage on Crinetics Pharmaceuticals in a report on Tuesday, February 4th. They issued a "peer perform" rating for the company. Stifel Nicolaus began coverage on Crinetics Pharmaceuticals in a report on Tuesday, March 25th. They issued a "buy" rating and a $60.00 target price for the company. Finally, TD Cowen began coverage on Crinetics Pharmaceuticals in a report on Tuesday, February 11th. They issued a "buy" rating for the company. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat.com, Crinetics Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $73.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CRNX. Venturi Wealth Management LLC acquired a new position in shares of Crinetics Pharmaceuticals during the 4th quarter valued at about $41,000. State of Wyoming acquired a new position in shares of Crinetics Pharmaceuticals during the 4th quarter valued at about $50,000. Headlands Technologies LLC acquired a new position in shares of Crinetics Pharmaceuticals during the 4th quarter valued at about $52,000. Harvest Fund Management Co. Ltd acquired a new position in shares of Crinetics Pharmaceuticals during the 4th quarter valued at about $66,000. Finally, GF Fund Management CO. LTD. increased its stake in shares of Crinetics Pharmaceuticals by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 2,375 shares of the company's stock valued at $80,000 after acquiring an additional 428 shares during the last quarter. Institutional investors and hedge funds own 98.51% of the company's stock.

Insider Activity

In other Crinetics Pharmaceuticals news, insider Dana Pizzuti sold 2,515 shares of the company's stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $34.20, for a total value of $86,013.00. Following the completion of the transaction, the insider now owns 72,233 shares in the company, valued at $2,470,368.60. This represents a 3.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Richard Scott Struthers sold 17,338 shares of the company's stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $34.20, for a total value of $592,959.60. Following the completion of the transaction, the chief executive officer now owns 329,147 shares of the company's stock, valued at approximately $11,256,827.40. This represents a 5.00% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,015 shares of company stock valued at $923,913 in the last 90 days. 4.60% of the stock is currently owned by insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.